Navigation Links
Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
Date:9/8/2011

SAN DIEGO, Sept. 8, 2011 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the initiation of a Phase I clinical trial of the Company's lead drug candidate ME-143 in patients with refractory solid tumors. The trial is being conducted in collaboration with the Sarah Cannon Research Institute in Nashville, Tennessee, following the approval of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) last month.

This Phase I dose-escalation trial will evaluate the safety and tolerability of intravenous ME-143 in patients with refractory solid tumors. In addition, the trial is designed to characterize the pharmacokinetic profile of intravenous ME-143 and describe any preliminary clinical anti-tumor activity observed. The open-label trial is expected to enroll up to 24 patients with final data collected by the second quarter of 2012.

"We are excited to begin treating patients with ME-143, a promising drug candidate that has demonstrated anti-tumor activity in pre-clinical studies," said Robert D. Mass, MD, Chief Medical Officer of Marshall Edwards. "Together with the Sarah Cannon Research Institute, we will be obtaining important information regarding dosing, safety and potential efficacy of intravenous ME-143 over the next several months, which will inform the design of our randomized Phase II clinical trials in combination with standard-of-care chemotherapy."

Additional information regarding this trial, entitled "Phase I Open Label Multicenter Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 in Patients with Refractory Solid Tumors," including enrollment criteria and site information, is available on the U.S. National Institutes of Health (NIH) clinical trials database at www.clinicaltrials.gov.

About ME-143

ME-143 is the lead oncology drug candidate from Marshall Edwards' NADH oxidase inhibitor program. It was derived from a proprietary isoflavone technology platform that has generated a number of compounds with anti-proliferative activity against tumor cells in laboratory studies. In pre-clinical studies, ME-143 has demonstrated potent activity against a number of tumor cell lines, including breast, colorectal and ovarian. In addition to broad single-agent activity, ME-143 has also shown an ability to enhance the cytotoxic effects of chemotherapy in pre-clinical studies. Marshall Edwards owns exclusive worldwide rights to ME-143. ME-143 is an investigational drug and has not been approved by the FDA for commercial distribution in the U.S. or other countries.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143. The second is a mitochondrial inhibitor program that includes lead candidate ME-344. The Company initiated a Phase I clinical trial of intravenous ME-143 in September 2011 and expects to submit an IND application for ME-344 by the first quarter of 2012. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


'/>"/>
SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
2. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
3. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
4. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
5. Marshall Edwards Announces Private Placement
6. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
7. Marshall Edwards Receives Positive Response From NASDAQ
8. Marshall Edwards to Host Annual Meeting of Stockholders
9. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
10. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
11. Medical Device Consultants, Inc. Welcomes Brian Edwards, Senior Regulatory Staff Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Biotechnology Inc., spurred by a major "team investment" by Bruce Montgomery , one of this ... A-Round, according to CEO Leen Kawas , PhD. ... ... ... Kawas said the round was intended ...
(Date:2/11/2016)... SAN JOSE, Calif. , Feb. 11, 2016 ... that pioneered the use of the iFuse Implant ... for fusion for certain disorders of the sacroiliac ... studies showing the cost benefits of MIS SI ... joint dysfunction due to degenerative sacroiliitis or SI ...
(Date:2/11/2016)... 11, 2016  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ... made at the 38th annual John A. Boswick ... which is being held February 14-18, 2016 in ... latest advancements in wound healing, burn care, and infection ... Australian-New Zealand Burns Association, Academy of Physicians in Wound ...
Breaking Medicine Technology:
(Date:2/11/2016)... Utah (PRWEB) , ... February 11, 2016 , ... ... microFET medical dynamometers and ergoFET force gauges used in physical therapy, occupational therapy ... Strength Indicator sensor for resistance cord exercise and therapy, introduces its new microFET ...
(Date:2/11/2016)... ... , ... The book, “Computers Should Just Work!”, provides a basic, non-techie education ... consultant before signing a contract and how to spot an incompetent or dishonest IT ... on e-mail and technology, it’s more important than ever to make sure the company ...
(Date:2/10/2016)... ... February 10, 2016 , ... President Obama’s ... Advantage organizations to deliver medical services via telehealth, estimated to generate more than ... for such language for many years. Although there is more to be ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Early this ... celebrate and raise awareness of Nestlé KITKAT as the first global confectionery brand sourced ... of cocoa farmers and the quality of their product, through activities that focus on ...
(Date:2/10/2016)... ... February 10, 2016 , ... Western University of ... services to the developmentally disabled in the Coachella Valley. , The two entities, ... facility at 71-949 Highway 111, Suite 100-B, in Rancho Mirage, California. The new ...
Breaking Medicine News(10 mins):